Literature DB >> 21705806

An ABCA1-independent pathway for recycling a poorly lipidated 8.1 nm apolipoprotein E particle from glia.

Jianjia Fan1, Sophie Stukas, Charmaine Wong, Jennifer Chan, Sharon May, Nicole DeValle, Veronica Hirsch-Reinshagen, Anna Wilkinson, Michael N Oda, Cheryl L Wellington.   

Abstract

Lipid transport in the brain is coordinated by glial-derived lipoproteins that contain apolipoprotein E (apoE) as their primary protein. Here we show that apoE is secreted from wild-type (WT) primary murine mixed glia as nascent lipoprotein subspecies ranging from 7.5 to 17 nm in diameter. Negative-staining electron microscropy (EM) revealed rouleaux, suggesting a discoidal structure. Potassium bromide (KBr) density gradient ultracentrifugation showed that all subspecies, except an 8.1 nm particle, were lipidated. Glia lacking the cholesterol transporter ABCA1 secreted only 8.1 nm particles, which were poorly lipidated and nondiscoidal but could accept lipids to form the full repertoire of WT apoE particles. Receptor-associated-protein (RAP)-mediated inhibition of apoE receptor function blocked appearance of the 8.1 nm species, suggesting that this particle may arise through apoE recycling. Selective deletion of the LDL receptor (LDLR) reduced the level of 8.1 nm particle production by approximately 90%, suggesting that apoE is preferentially recycled through the LDLR. Finally, apoA-I stimulated secretion of 8.1 nm particles in a dose-dependent manner. These results suggest that nascent glial apoE lipoproteins are secreted through multiple pathways and that a greater understanding of these mechanisms may be relevant to several neurological disorders.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21705806      PMCID: PMC3151681          DOI: 10.1194/jlr.M014365

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  84 in total

1.  The recycling of apolipoprotein E in macrophages: influence of HDL and apolipoprotein A-I.

Authors:  Alyssa H Hasty; Michelle R Plummer; Karl H Weisgraber; Macrae F Linton; Sergio Fazio; Larry L Swift
Journal:  J Lipid Res       Date:  2005-04-01       Impact factor: 5.922

2.  Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I.

Authors:  Jenelle M Timmins; Ji-Young Lee; Elena Boudyguina; Kimberly D Kluckman; Liam R Brunham; Anny Mulya; Abraham K Gebre; Jonathan M Coutinho; Perry L Colvin; Thomas L Smith; Michael R Hayden; Nobuyo Maeda; John S Parks
Journal:  J Clin Invest       Date:  2005-04-07       Impact factor: 14.808

3.  Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease.

Authors:  Terry L Lewis; Dongfeng Cao; Hailin Lu; Robert A Mans; Yan Ru Su; Lisa Jungbauer; MacRae F Linton; Sergio Fazio; Mary Jo LaDu; Ling Li
Journal:  J Biol Chem       Date:  2010-09-16       Impact factor: 5.157

4.  Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent.

Authors:  U Beffert; J S Cohn; C Petit-Turcotte; M Tremblay; N Aumont; C Ramassamy; J Davignon; J Poirier
Journal:  Brain Res       Date:  1999-10-02       Impact factor: 3.252

5.  Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice.

Authors:  A M Fagan; D M Holtzman; G Munson; T Mathur; D Schneider; L K Chang; G S Getz; C A Reardon; J Lukens; J A Shah; M J LaDu
Journal:  J Biol Chem       Date:  1999-10-15       Impact factor: 5.157

6.  Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation.

Authors:  Joerg Heeren; Thomas Grewal; Alexander Laatsch; Nils Becker; Franz Rinninger; Kerry-Anne Rye; Ulrike Beisiegel
Journal:  J Biol Chem       Date:  2004-10-12       Impact factor: 5.157

7.  Modulation of apolipoprotein E structure by domain interaction: differences in lipid-bound and lipid-free forms.

Authors:  Danny M Hatters; Madhu S Budamagunta; John C Voss; Karl H Weisgraber
Journal:  J Biol Chem       Date:  2005-08-01       Impact factor: 5.157

8.  Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels.

Authors:  Hiroaki Fukumoto; Marsha Tennis; Joseph J Locascio; Bradley T Hyman; John H Growdon; Michael C Irizarry
Journal:  Arch Neurol       Date:  2003-07

9.  Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice.

Authors:  P M Sullivan; B E Mace; N Maeda; D E Schmechel
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

10.  Morphology and structure of lipoproteins revealed by an optimized negative-staining protocol of electron microscopy.

Authors:  Lei Zhang; James Song; Giorgio Cavigiolio; Brian Y Ishida; Shengli Zhang; John P Kane; Karl H Weisgraber; Michael N Oda; Kerry-Anne Rye; Henry J Pownall; Gang Ren
Journal:  J Lipid Res       Date:  2010-10-26       Impact factor: 5.922

View more
  14 in total

1.  Hormonal modulators of glial ABCA1 and apoE levels.

Authors:  Jianjia Fan; Yoko Shimizu; Jeniffer Chan; Anna Wilkinson; Ayaka Ito; Peter Tontonoz; Edie Dullaghan; Liisa A M Galea; Tom Pfeifer; Cheryl L Wellington
Journal:  J Lipid Res       Date:  2013-09-02       Impact factor: 5.922

2.  High-density lipoprotein mimetic peptide 4F mitigates amyloid-β-induced inhibition of apolipoprotein E secretion and lipidation in primary astrocytes and microglia.

Authors:  Dustin Chernick; Stephanie Ortiz-Valle; Angela Jeong; Suresh K Swaminathan; Karunya K Kandimalla; G William Rebeck; Ling Li
Journal:  J Neurochem       Date:  2018-11-26       Impact factor: 5.372

3.  LCAT deficiency does not impair amyloid metabolism in APP/PS1 mice.

Authors:  Sophie Stukas; Lita Freeman; Michael Lee; Anna Wilkinson; Alice Ossoli; Boris Vaisman; Stephen Demosky; Jeniffer Chan; Veronica Hirsch-Reinshagen; Alan T Remaley; Cheryl L Wellington
Journal:  J Lipid Res       Date:  2014-06-20       Impact factor: 5.922

Review 4.  Cell-specific production, secretion, and function of apolipoprotein E.

Authors:  Maaike Kockx; Mathew Traini; Leonard Kritharides
Journal:  J Mol Med (Berl)       Date:  2018-03-07       Impact factor: 4.599

5.  AP-2β regulates amyloid beta-protein stimulation of apolipoprotein E transcription in astrocytes.

Authors:  Ximena S Rossello; Urule Igbavboa; Gary A Weisman; Grace Y Sun; W Gibson Wood
Journal:  Brain Res       Date:  2012-01-18       Impact factor: 3.252

6.  Apolipoprotein E isoform-specific effects on lipoprotein receptor processing.

Authors:  Corbin Bachmeier; Ben Shackleton; Joseph Ojo; Daniel Paris; Michael Mullan; Fiona Crawford
Journal:  Neuromolecular Med       Date:  2014-12       Impact factor: 3.843

Review 7.  Impact of apolipoprotein E on Alzheimer's disease.

Authors:  Paul S Hauser; Robert O Ryan
Journal:  Curr Alzheimer Res       Date:  2013-10       Impact factor: 3.498

8.  Small molecule inducers of ABCA1 and apoE that act through indirect activation of the LXR pathway.

Authors:  Jianjia Fan; Rui Qi Zhao; Cameron Parro; Wenchen Zhao; Hsien-Ya Chou; Jerome Robert; Tarek Z Deeb; Carina Raynoschek; Samantha Barichievy; Ola Engkvist; Marcello Maresca; Ryan Hicks; Johan Meuller; Stephen J Moss; Nicholas J Brandon; Michael W Wood; Iva Kulic; Cheryl L Wellington
Journal:  J Lipid Res       Date:  2018-03-21       Impact factor: 5.922

9.  In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis.

Authors:  Jason D Ulrich; Jack M Burchett; Jessica L Restivo; Dorothy R Schuler; Philip B Verghese; Thomas E Mahan; Gary E Landreth; Joseph M Castellano; Hong Jiang; John R Cirrito; David M Holtzman
Journal:  Mol Neurodegener       Date:  2013-04-19       Impact factor: 14.195

10.  Improvement of memory deficits and amyloid-β clearance in aged APP23 mice treated with a combination of anti-amyloid-β antibody and LXR agonist.

Authors:  Nicholas F Fitz; Emilie L Castranio; Alexis Y Carter; Ravindra Kodali; Iliya Lefterov; Radosveta Koldamova
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.